Active Ingredient History

NOW
  • Now
Perampanel (trade name Fycompa) is an antiepileptic drug developed by Eisai Co. that acts as a selective non-competitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. Although the mechanism of action through which perampanel exerts its antiepileptic effect has not been fully elucidated, this agent antagonizes the AMPA subtype of the excitatory glutamate receptor found on postsynaptic neurons in the central nervous system (CNS). This antagonistic action prevents AMPA receptor activation by glutamate and results in the inhibition of neuronal excitation, repetitive neuronal firing, and the stabilization of hyper-excited neural membranes. Glutamate, the primary excitatory neurotransmitter in the CNS, plays an important role in various neurological disorders caused by neuronal hyperexcitation. The drug is currently approved, for the control of partial-onset seizures, in those of both sexes who suffer from epilepsy and who are 12 years of age and older, by the Food and Drug Administration. Perampanel is also approved for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. It is designated as a Schedule III controlled substance by the Drug Enforcement Administration. Perampanel has been studied in other clinical indications including Parkinson's disease.   NCATS

  • SMILES: O=C1N(C=C(C=C1C2=C(C=CC=C2)C#N)C3=NC=CC=C3)C4=CC=CC=C4
  • InChIKey: PRMWGUBFXWROHD-UHFFFAOYSA-N
  • Mol. Mass: 349.3847
  • ALogP: 4.44
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

Australia

$2.1764 - $8.7058

United States

$3.8211 - $995.5300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one | e2007 | e-2007 | er-155055-90 | fycompa | perampanel | pérampanel | perampanelum

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue